KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.

Claudia Campani, Ju Hyun Shim, Mohamed Bouattour, Yann Touchefeu, Victoria Delhoume, Olivier Rosmorduc, Alina Pascale, Jihyun An, Han Chu Lee, Helene Regnault, Dominique Thabut, Giuliana Amaddeo, Massih Ningarhari, Isabelle Ollivier-Hourmand, Chloé Métivier, Maxime Ronot, Line Ntandaja-Wandji, Violaine Ozenne, Sabrina Sidali, Fabio Marra, Clemence Hollande, Nathalie Ganne-Carrié, Pierre Nahon, Jean-Marie Peron, Marie Lequoy, Rohini Sharma, Paris Liver Cancer Group, Manon Allaire, Jean-Charles Nault

Clin Cancer Res 10.1158/1078-0432.CCR-25-4943

PMID42008357
PMCID-
DOI10.1158/1078-0432.CCR-25-4943
发表日期2026-04-20
摘要

摘要

BACKGROUND & AIMS: Immune checkpoint inhibitors (ICIs) can induce long-term survival and even cancer cure in several cancers. Mixture cure models (MCMs) estimate the fraction of long-term survivors and cured patients but have not been applied in HCC. METHODS: We identified phase 3 randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of HCC patients treated with atezolizumab-bevacizumab. After reconstructing Kaplan-Meier curves, MCMs estimated long-term survivors' fraction (overall survival, OS) and cure fractions (progression-free survival, PFS). RESULTS: In HIMALAYA (median follow-up of 60 months), long-term survival was 12.8% (95%CI:8.5-18.6%) with durvalumab-tremelimumab versus 5.2% (95%CI:2.6-10.2%) with sorafenib; cure fraction was not assessable.In CheckMate9DW (median follow-up: 35.2 month), long-term survival was 8.7% (95%CI:0.2-81.3%) versus 4.1% (95%CI:0.1-66.1%) and cure fractions were 17.8% (95%CI:12.0-25.8%) versus 3.5% (95%CI:0.7-16.7%) for nivolumab-ipilimumab and sorafenib/lenvatinib respectively with long-term OS estimates remaining exploratory due to limited late numbers at risk.In RATIONALE-301, long-term survival was 25.2% (95%CI:19.2-32.2) with tislelizumab versus 15.4% (95%CI: 10.0-22.8) with sorafenib. IMbrave150 trial was not analyzed due to insufficient follow-up (15.6 months). Among a clinical cohort of 1581 patients treated by atezolizumab-bevacizumab (median follow-up: 34.7 months), long-term survival was 12.3% (95%CI:9.3-16.1%) and cure fraction 7.9% (95%CI:6.3-9.8%). In 1187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95%CI:10.6-18.5%) and cure fraction 9.1% (95%CI:7.3-11.4%).ALBI score, and hepatitis C predicted long-term survival and albumin and hepatitis C predicted cure. CONCLUSION: Across trials and real-world data, ICIs combinations achieve long-term survival in 10-15% of advanced HCC patients, with cure fractions of 7-9%.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。